Clinical and economic review of erlotinib in non-small-cell lung cancer

References

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212–236 (2011).
   PubMed Web of Science ®Google Scholar
• Center M, Siegel R, Jemal A. American Cancer Society: Global Cancer Facts & Figures (2nd Edition). American Cancer Society Inc., GA, USA (2011).
   Google Scholar
• Midthun D. Overview of the initial evaluation, treatment and prognosis of lung cancer. In: UpToDate. Basow D (Ed.). UpToDate, MA, USA (2012).
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small-Cell Lung Cancer. National Comprehensive Cancer Network, USA (2012).
   Google Scholar
• Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small-cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(Suppl. 3), S243–S265 (2007).
   Google Scholar
• Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 16(4), 486–496 (2011).
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27(20), 3284–3289 (2009).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results – Medicare. J. Clin. Oncol. 22(24), 4971–4978 (2004).
   PubMed Web of Science ®Google Scholar
• Gervais R, Rosell R, Vergnenegre A. The EURTAC (European Tarceva® vs Chemotherapy) study: interim results of a Phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations. J. Thorac. Oncol. 6(6 Suppl. 2), S314–S315 (2011).
   Google Scholar
• Zhou C, Wu Y, Chen G. Efficacy results from the randomised Phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDC A) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann. Oncol. 21(Suppl. 8), viii6 (2010).
   Google Scholar
• Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735–742 (2011).
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364(10), 947–955 (2011).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R et al.; TRIBUTE Investigator Group. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Jänne PA, Rochelle JM, Martin-DeLeon PA, Stambolian D, Seldin MF, Nussbaum RL. Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens. Genomics 28(2), 280–285 (1995).
   PubMedGoogle Scholar
• Rosell R, Carcereny E, Gervais R et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Midthun D. Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor. In: UptoDate. Basow D (Ed.). UpToDate, MA, USA (2012).
   Google Scholar
• EMA. Erlotinib (Tarceva) summary of opinion (post authorisation). EMA, London, UK (2011).
   Google Scholar
• Gridelli C, Maione P, Rossi A et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 14(2), 137–147 (2009).
   PubMed Web of Science ®Google Scholar
• Neal JW. The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol. 6(12), 1827–1832 (2010).
   PubMed Web of Science ®Google Scholar
• Miller VA, O’Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl. 18) (2009) (Abstract LBA8002).
   Google Scholar
• Belani P, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized Phase III study in advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 27 (2009) (Abstract CRA8000).
   Google Scholar
• Permetrexed. Prescribing information. Eli Lilly and Company, IN, USA (2011).
   Google Scholar
• Tarceva®. Prescribing information.Genentech, CA, USA (2010).
   Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Chouaid C, Le Caer H, Crequit J et al. Cost–effectiveness of erlotinib in first-line treatment of advanced non-small-cell lung cancer (NSCLC) in fit elderly patients: an economical analysis of a prospective Phase 2 study (GFPC 0504). Value Health 13(7), A267 (2010).
   Google Scholar
• Krawczyk P, Kowalski DM, Wojas-Krawczyk K et al. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. Chemotherapy 58(1), 60–69 (2012).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small-Cell Lung Cancer V.1.2009. National Comprehensive Cancer Network, USA (2009).
   Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Jones D. Avastin–Tarceva combination fails in lung cancer. Nat. Biotechnol. 27(2), 108–109 (2009).
   PubMedGoogle Scholar
• Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161), 771–775 (1998).
   PubMed Web of Science ®Google Scholar
• Juhasz E, Kim JH, Stelmakh L, Cicenas S, Klingelschmitt G. Erlotinib maintenance therapy for non-small-cell lung cancer preserves quality of life. Value Health 13(7), A276–A277 (2010).
   Google Scholar
• Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 13(11), 1201–1204 (2008).
   PubMedGoogle Scholar
• Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin. J. Oncol. Nurs. 12(2), 283–290 (2008).
   PubMedGoogle Scholar
• Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5), 345–356 (2005).
   PubMed Web of Science ®Google Scholar
• Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med. Oncol. 23(2), 161–170 (2006).
   PubMedGoogle Scholar
• Ohe Y, Fakuoka M, Kudoh S et al. Post-marketing surveillance of erlotinib for NSCLC in Japan: interim analyses of 3,488 patients. J. Clin. Oncol. 29 (2011) (Abstract e18007).
   Google Scholar
• Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Lung Cancer 51(1), 115–121 (2006).
   PubMed Web of Science ®Google Scholar
• van Zandwijk N. Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. Lung Cancer 51(1), 137–138 (2006).
   PubMedGoogle Scholar
• Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am. J. Manag. Care 14(5), 297–306 (2008).
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, de Castro Carpeño J, Chouaid C et al. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer 76(3), 465–471 (2012).
   PubMedGoogle Scholar
• Lash S, Teitelbaum A, Henk HJ, Reyes CM, Benn L. Costs associated with second-line therapies for lung cancer. Am. J. Pharm. Benefit 3(1), 21–33 (2011).
   Google Scholar
• Castro De Carpeno J, Castro-Gomez AJ, Walzer S, Ray J. Cost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer in Spain. Value Health 13(7), A259 (2010).
   Google Scholar
• Ravera S, Walzer S, Ray J. Cost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer in Italy. Value Health 13(7), A259 (2010).
   Web of Science ®Google Scholar
• Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small-cell lung cancer: impact on the budget of a U.S. health insurance plan. J. Manag. Care Pharm. 12(6), 472–478 (2006).
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Wong WB, Veenstra DL, Reyes C. Budget impact of erlotinib for maintenance therapy in advanced non-small-cell lung cancer. J. Med. Econ. 14(2), 159–166 (2011).
   PubMedGoogle Scholar
• Surveillance, Epidemiology and End Results. Surveillance, Epidemiology, and End Results (SEER) program, SEER-17 registry, public use dataset 2004–2007. Surveillance, Epidemiology and End Results, MD, USA (2010).
   Google Scholar
• Docetaxel. Prescribing information. Hospira, IL, USA (2011).
   Google Scholar
• Clark O, Clark LG, Botrel TE et al. Budgetary impact of adoption of erlotinib for lung cancer in the private health insurance market in Brazil: a real world data analysis. Value Health 14(7), A438–A439 (2011).
   PubMedGoogle Scholar
• Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20–27 (2009).
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small-cell lung cancer (NSCLC). Lung Cancer 61(3), 405–415 (2008).
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Tu D, Seymour L et al.; NCIC Clinical Trials Group Working Group on Economic Analysis. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small-cell lung cancer. J. Natl Cancer Inst. 102(5), 298–306 (2010).
   PubMed Web of Science ®Google Scholar
• Dickson R, Bagust A, Boland A et al. Erlotinib monotherapy for the maintenance treatment of non-small-cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics 29(12), 1051–1062 (2011).
   PubMed Web of Science ®Google Scholar
• Lewis G, Peake M, Aultman R et al. Cost–effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J. Int. Med. Res. 38(1), 9–21 (2010).
   PubMed Web of Science ®Google Scholar
• McLeod C, Bagust A, Boland A et al. Erlotinib for the treatment of relapsed non-small-cell lung cancer. Health Technol. Assess. 13(Suppl. 1), 41–47 (2009).
   PubMedGoogle Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Cromwell I, van der Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small-cell lung cancer: a real-world cost–effectiveness analysis. J. Thorac. Oncol. 6(12), 2097–2103 (2011).
   PubMedGoogle Scholar
• Vergnenègre A, Ray JA, Chouaid C et al. Cross-market cost–effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small-cell lung cancer. Clinicoecon. Outcomes Res. 4, 31–37 (2012).
   PubMedGoogle Scholar
• Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Costs and clinical outcomes among patients with second-line non-small-cell lung cancer in the outpatient community setting. J. Thorac. Oncol. 7(1), 212–218 (2012).
   PubMed Web of Science ®Google Scholar
• Laurendeau C, Chouaid C, Florentin V, Duchon D’Engenières V, Detournay B. Cost-minimization analysis of second-line chemotherapy for non-small-cell lung cancer (NSCLC). Value Health 14(7), A440 (2011).
   Google Scholar
• Chouaid C, Le Caer H, Corre R et al. Cost–effectiveness of erlotinib in first line treatment of advanced non-small-cell lung cancer (NSCLC) in vulnerable elderly patients: an economical analysis of a prospective Phase 2 study (GFPC 0505). Value Health 14(7), A448 (2011).
   Google Scholar
• Pompen M, Novak A, Postmus P. Cost–effectiveness analysis of erlotinib in The Netherlands. Value Health 9(6), A203 (2006).
   Google Scholar
• Terres R, Sanz A, Gylmark M. Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small-cell lung cancer who have failed previous chemotherapy regimens. Value Health 9(6), A283 (2006).
   Google Scholar
• Lewis G, Morlotti L, Creeden J. Cost–effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in the UK. Value Health 9(6), A203 (2006).
   Google Scholar
• NICE. ERG report: erlotinib for the treatment of relapsed non-small-cell lung cancer. NICE, UK (2006).
   Google Scholar
• Ciuleanu TE, Dediu M, Minea LN, Baculea S, Szkultecka-Debek M. Cost–effectiveness analysis of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in Romania. Value Health 13(3), A38 (2010).
   Google Scholar
• Nguyen TT, Yagudina R, Kulikov A. Cost–effectiveness analysis of erlotinib versus docetaxel, pemetrexed for second-line treatment of advanced non-smallcell lung cancer in Russia. Value Health 14(7), A450 (2011).
   PubMedGoogle Scholar
• Orlewska E, Szczesna A, Gyldmark M. Cost–effectiveness of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in Poland. Value Health 9(6), A279 (2006).
   Google Scholar
• Santos EA, Buschinelli CT, Ferracini M, Pepe C, Estanislao M. Erlotinib as second line treatment for advanced non-small-cell lung cancer (NSCLC): economic modeling (EM) results. Value Health 14(7), A446 (2011).
   Google Scholar
• Terres R, Sanz A, Gylmark M. Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small-cell lung cancer who have failed previous chemotherapy regimens. Value Health 9(6), A283–A284 (2006).
   Google Scholar
• Borget I, Cadranel J, Mauguen A et al. Cost–effectiveness analysis of three strategies of erlotinib treatment in non-small-cell lung cancer: a prospective multicentric French study (ERMETIC). Value Health 13(7), A266 (2010).
   Google Scholar
• Borget I, Cadranel J, Pignon JP et al.; ERMETIC Collaborative Group. Cost–effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Eur. Respir. J. 39(1), 172–179 (2012).
   PubMed Web of Science ®Google Scholar
• Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121–2127 (2011).
   PubMed Web of Science ®Google Scholar
• Côté I, Leighl N, Gyldmark M, Maturi B. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small-cell lung cancer (NSCLC) from the Canadian public health care perspective. Value Health 9(6), A279 (2006).
   Google Scholar
• Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121–2127 (2011).
   PubMedGoogle Scholar
• de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost–effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032–1039 (2012).
   PubMedGoogle Scholar
• Brown T, Boland A, Bagust A et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. Health Technol. Assess. 14(Suppl. 2), 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• EMA. Evaluation of Medicines for Human Use. Assessment Report for Iressa®. EMA, London, UK (2012).
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12(11), 1004–1012 (2011).
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 12(12), 3657–3660 (2006).
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, Phase 3 study. Lancet Oncol. 13(3), 300–308 (2012).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ciardiello F, Feld R et al. International multicenter randomized Phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small-cell lung cancer (aNSCLC): the TORCH trial. J. Clin. Oncol. 28(15), A7508 (2010).
   Google Scholar
• Carlson JJ. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 409–416 (2009).
   PubMedGoogle Scholar
• Orlewska E, Szczesna A, Gyldmark M. Cost–effectiveness of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in poland. Value Health 9(6), A280 (2006).
   Google Scholar